BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CPO301 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CPO301\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07256509-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:CPO301: Phase 2 readout est. (NCT07256509)
DESCRIPTION:CPO301\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuva
 nt Therapy for Patients With EGFR Mutation-positive Resectable Non-squamou
 s Non-small Cell Lung Cancer\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07256509
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:CPO301: Phase 3 readout est. (NCT07376382)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients 
 With Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 1
 2 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo3
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7376382
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05948865-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:CPO301: Phase 1 readout est. (NCT05948865)
DESCRIPTION:CPO301\, phase 1.\nStudy: A Phase 1 Study of CPO301 in Adult Pa
 tients With Advanced or Metastatic Solid Tumors\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 48865
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775236-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:CPO301: Phase 1/2 readout est. (NCT06775236)
DESCRIPTION:CPO301\, phase 1/2\, Breast Cancer.\nStudy: Clinical Trial of S
 YS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other So
 lid Tumors\nEstimated primary completion: 15 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06775236
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CPO301: Phase 3 readout est. (NCT07633873)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemothera
 py for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC
 （SYNSTAR 04）\nEstimated primary completion: 30 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241936-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:CPO301: Phase 1/2 readout est. (NCT07241936)
DESCRIPTION:CPO301\, phase 1/2.\nStudy: A Study of Sirolimus (Albumin-Bound
 ) in Combination With Different ADCs Treatment of Advanced Solid Tumors\nE
 stimated primary completion: 30 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07241936
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442565-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:CPO301: Phase 3 readout est. (NCT07442565)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07442565
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692048-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:CPO301: Phase 1 readout est. (NCT07692048)
DESCRIPTION:CPO301\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally 
 Advanced or Metastatic NSCLC\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07692048
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254585-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:CPO301: Phase 2 readout est. (NCT07254585)
DESCRIPTION:CPO301\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nStud
 y: SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And 
 Neck Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07254585
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758621-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:CPO301: Phase 3 readout est. (NCT07758621)
DESCRIPTION:CPO301\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nStud
 y: SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurr
 ent or Metastatic HNSCC\nEstimated primary completion: 15 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07758621
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417735-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:CPO301: Phase 3 readout est. (NCT07417735)
DESCRIPTION:CPO301\, phase 3.\nStudy: SYS6010 Versus Chemotherapy in Locall
 y Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07417735
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:CPO301: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:CPO301\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SYS609
 0 Combination Therapy in Advanced Lung Cancer\nEstimated primary completio
 n: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cpo301#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07472647
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406542-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:CPO301: Phase 3 readout est. (NCT07406542)
DESCRIPTION:CPO301\, phase 3\, Breast Cancer.\nStudy: A Phase III Study of 
 SYS6010 Versus Chemotherapy in HER2-Negative\, EGFR-Positive Recurrent or 
 Metastatic Breast Cancer\nEstimated primary completion: 1 April 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07406542
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672223-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:CPO301: Phase 3 readout est. (NCT07672223)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 Septem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672223
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925021-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:CPO301: Phase 3 readout est. (NCT07925021)
DESCRIPTION:CPO301\, phase 3.\nStudy: A Study of SYS6010 Combined With Enlo
 nstobart in Patients With Previously Systemic Treatment-Naive R/M Nasophar
 yngeal Carcinoma\nEstimated primary completion: 1 October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07925021
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251062-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:CPO301: Phase 2/3 readout est. (NCT07251062)
DESCRIPTION:CPO301\, phase 2/3.\nStudy: A Study of SYS6010\, Enlonstobart\,
  and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Car
 cinoma.\nEstimated primary completion: 30 December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07251062
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924111-2211@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:CPO301: Phase 3 readout est. (NCT07924111)
DESCRIPTION:CPO301\, phase 3.\nStudy: A Randomized\, Controlled\, Double-Bl
 ind\, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Sa
 fety of Enlonstobart\, With or Without SYS6010 as Adjuvant Therapy\, in Pa
 rticipants With Pathologically Residual Esophageal Squamous Cell Carcinoma
  Following Complete Surgical Resection\nEstimated primary completion: 30 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0792
 4111
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
